The PI3K/AKT pathway, which regulates tumor cell proliferation, survival, and metabolism, is frequently aberrantly activated in UCS (1, 18).Although PI3K/AKT pathway status was not assessed in this case, inhibitors targeting this pathway are under clinical evaluation and represent a potential therapeutic option. Here, AKT1 is linked to neoplasm.